Abbott Laboratories
—- Market cap
- $180.03B
- Debt
- —
- Cash
- −$8.52B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $180.03B · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
FY 2025 ·
Decision snapshot: ABT stock price at discount vs DHR $103.36 current versus $147.72 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DHR's multiple
Implied fair value · at ABT's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Lower P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 88% equity / 12% debt
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ABBOTT LABORATORIES · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
DANAHER CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ABT can re-rate to DHR's P/E (39.3x) and investors will reward ABT's stronger revenue growth and ROIC, then buy to a $146.30 ABT because ABT is materially cheaper on P/E, P/S and EV/EBITDA and would capture ~44.8% upside on re-rating; if you believe market will prioritize quality/cash (Piotroski 4/9, Net Debt/EBITDA 0.6x) and keep the multiple gap, then remain neutral or wait for evidence of durable margin or quality improvement.
ABT's current price ($101.05) implies a 44.8% upside to $146.30 on a DHR-based P/E re-rate to DHR; the stock sits inside its historical band but well below DHR-implied top of range. The P/E, P/S and EV/EBITDA comparisons show ABT is materially cheaper than DHR, creating the observed valuation gap.
Supporting Metrics